GlassScriptPhysician profile
Raquel Appa Falcao
NPI 1114219839
$4,944.85
in general payments reported to CMS, 2019-2025
36 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $287 · 2021: $824 · 2022: $1,355 · 2023: $932 · 2024: $276 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $615.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $589.00 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $562.30 | 2019-2025 | Evenity |
| Abbott Laboratories | $434.48 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $364.73 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $329.08 | 2019-2023 | Breztri, Farxiga |
| Pfizer INC. | $323.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.16 | 2021-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $136.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $113.66 | 2019-2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $110.68 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.40 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $103.41 | 2019-2022 | |
| Esperion Therapeutics, INC. | $97.01 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $96.40 | 2020-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $75.64 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $65.06 | 2019-2023 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $53.30 | 2022 | |
| Astellas Pharma US INC | $51.20 | 2019 | |
| Allergan, INC. | $51.00 | 2019-2020 | |
| Exact Sciences Corporation | $44.21 | 2024 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $43.91 | 2023 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $40.47 | 2022-2023 | Yupelri |
| Avanir Pharmaceuticals, INC. | $40.09 | 2019-2022 | |
| Inspire Medical Systems, INC. | $39.08 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $37.62 | 2022-2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $30.66 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $20.22 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.33 | 2022 | |
| Daiichi Sankyo INC. | $17.29 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.49 | 2020 | |
| Vanda Pharmaceuticals INC. | $14.63 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.23 | 2022 | |
| Eisai INC. | $12.05 | 2019 | |
| Shire North American Group INC | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Appa Falcao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.